{"doi":"10.1093/rap/rkaf049","title":"Anti-PCNA antibodies in psoriatic arthritis: a case–control study","abstract":"Abstract Objectives Psoritic arthritis (PsA) is an inflammatory arthritis with infrequent antibodies. We present a case–control study of six PsA patients with antibodies against PCNA and observed clinical associations. Methods We conducted a study to identify autoantibodies in PsA. Sera from 81 PsA patients were assayed by immunoprecipitation from radiolabelled cell extracts. From this study, serum that immunoprecipitated a ≈32-kDa band was selected for mass spectrometry–based antibody discovery, which identified anti-PCNA antibodies. These were validated using immunoprecipitation of 35S-methionine-labelled PCNA from in vitro transcription and translation. This assay tested 222 PsA sera for anti-PCNA antibodies. This study included sera from 39 healthy controls. Descriptive statistics were used to assess clinical associations with anti-PCNA status. Results Anti-PCNA antibodies were identified in 6/222 PsA patients. In 4/6 patients, banked longitudinal sera were available. In patients with anti-PCNA positivity compared with negativity, the mean age was 46 years (s.d. 14) and 52 years (s.d. 13), PsA disease duration was 8 years (s.d. 7) and 7 years (s.d. 8), BMI was 27 (s.d. 4) and 31 (s.d. 7), 67% and 44% were male, 100% and 89% were White, mean clinical DAPSA was 16 (s.d. 22) and 21 (s.d. 16), psoriasis body surface area was 2% (s.d. 4) and 5% (s.d. 12), HLA-B27 positivity was 0 and 12% and sulfasalazine (SSZ) use was 83% and 10%, respectively. Of these, only SSZ use was significant (Fisher’s exact test P-value <0.001). Among anti-PCNA-positive patients with longitudinal sera, low/absent anti-PCNA coincided with articular low disease activity/remission. Conclusion Anti-PCNA antibodies were found in 6/222 (2.7%) PsA patients. Given the low prevalence of anti-PCNA, additional studies are needed to identify the clinical associations and significance.","journal":"Rheumatology Advances in Practice","year":2025,"id":564838,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9545,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":257453,"name":"Jemima Albayda","orcid":"0000-0002-8030-9504","position":1,"is_corresponding":false},{"id":1030979,"name":"Qingyuan Yang","orcid":"0000-0001-8808-1113","position":2,"is_corresponding":false},{"id":1468054,"name":"Ning Meng","orcid":"0009-0003-0081-8697","position":3,"is_corresponding":false},{"id":257451,"name":"Livia Casciola‐Rosen","orcid":"0000-0002-4172-1539","position":4,"is_corresponding":false},{"id":376863,"name":"Ana‐Maria Orbai","orcid":"0000-0001-8644-8567","position":5,"is_corresponding":false},{"id":1468053,"name":"Rebecca Fitzpatrick","orcid":"0000-0002-0913-8503","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":null,"created_at":"2026-07-19T02:56:24.872312Z","pmid":"40417241","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}